Successful Ultraviolet B Treatment of Psoriasis Is Accompanied by a Reversal of Keratinocyte Pathology and by Selective Depletion of Intraepidermal T Cells

By James G. Krueger, Jonathan T. Wolfe, Reiko Tsukifuji Nabeya, Val Pierre Vallat, Patricia Gilleaudeau, Noah S. Heftler, Lisa M. Austin, and Alice B. Gottlieb

From the Laboratory for Investigative Dermatology, The Rockefeller University, New York 10021

Summary
Skin irradiation with ultraviolet B (UVB) is a common and often durable treatment for psoriasis and other inflammatory skin disorders. We studied the effects of UVB on keratinocytes and leukocytes in psoriatic tissue and in culture. In nine patients treated repetitively, most of the cellular and molecular changes that typify the psoriatic epidermis reverted to normal. Keratinocyte hyperplasia, assessed by expression of the Ki-67 cell cycle antigen, decreased by 70%, and residual cell proliferation was appropriately confined to the basal layer. Epidermal thickening was reduced by 60%, and a granular layer reformed. Expression of keratin 16, as well as suprabasal integrin α3 and insulin-like growth factor-1 receptors, was eliminated, whereas filaggrin increased markedly. UVB also depleted >90% of the CD3+, CD8+, and CD25+ T cells from the psoriatic epidermis, whereas dermal T cells were only minimally depressed. The latter finding parallels the known inability of these doses of UVB to penetrate the dermis. In tissue culture, UVB was antiproliferative and cytotoxic toward T cells and keratinocytes, but the T cells were 10-fold more sensitive. Furthermore, low doses of UVB induced apoptosis in lymphocytes but not keratinocytes, as detected by the TUNEL (TdT-mediated dUTP-biotin nick end labeling) technique. The selective effects of UVB on intraepidermal T cells in situ and in culture support the hypothesis that epidermal alterations in psoriasis can be normalized by a depletion of activated intraepidermal T cells.

Psoriasis is a common skin disorder typified by hyperplasia and incomplete differentiation of epidermal keratinocytes. These epidermal changes parallel those seen in wound healing and are collectively termed the "regenerative phenotype." Molecular markers of this phenotype include the synthesis of such keratinocyte products as the α-3 protein and keratins 6 and 16, suprabasal expression of integrin α3 and IGF receptors, and reduced levels of the filaggrin and involucrin proteins that mediate keratin cross-linking and stratum corneum formation (1–3 and Gottlieb, S. L., E. Hayes, P. Gilleaudeau, I. Cardinale, A. B. Gottlieb, and J. G. Krueger, manuscript submitted for publication).

Psoriasis is also accompanied by an infiltration of activated T cells. CD25+ and CD3+ cells are found in both the epidermis and dermis, the former being predominantly CD8+ and the latter CD4+ (4–6). Both types of T cells have been proposed to play a pathogenic role (6, 7). A role for CD8+ cells is favored by the observed linkage of psoriasis to certain MHC I alleles, especially HLA Cw6 (8), and the skewing of CD8+ TCR Vβ usage to the Vβ 3 and 13.1 subtypes (9). Other inflammatory dermatoses are not accompanied by a high density of CD8+ T cells, especially activated CD25+ cells in the epidermis (10).

Aberrant keratinocyte proliferation, regenerative epidermal differentiation, and infiltration of CD8+ T cells in psoriatic epidermis were recently shown to be sensitive to a new therapeutic modality, the IL-2 diphtheria toxin conjugate DAB389 IL-2 (11). Since IL-2 directs the toxin to activated immune cells rather than to keratinocytes, a pathogenic role for T cells is indicated. The reciprocal also applies, i.e., psoriatic epidermal changes are only partly reversed by treatments (e.g., calcitriol, etretinate, or cyclosporine) that produce lesser reductions in infiltrating epidermal T cells (12, 13 and Lu, I., P. Gilleaudeau, J. A. McLane, N. Heftler, M. Kamber, S. Gottlieb, J. G. Krueger, and A. B. Gottlieb, manuscript submitted for publication).

Skin irradiation with ultraviolet light in the 280–320-nm range (ultraviolet B or UVB) is one of the most common treatments for extensive psoriasis and can produce long-lived clinical remissions. UVB can be immunosuppressive, possibly at the level of antigen-presenting dendritic cells (14, 15). UVB also has direct effects on T cells, including...
Ultraviolet B Treatment of Psoriasis

Untreated psoriasis

A

After UVB treatment

B

C

D

E

F

G

H

I

J
decreased TCR signaling, decreased lymphokine synthesis, and direct cytotoxicity (14-17). These UVB effects have been previously studied, chiefly in the context of the sensitization phase of the immune response. Much less information is available on the ability of UVB to modulate ongoing lymphocyte function in chronic disorders, especially in a human disease like psoriasis.

Here we describe findings on the effects of repetitive UVB therapy in nine consecutive patients with extensive psoriasis. UVB normalized a large group of cellular and molecular disease markers, but primarily reversed the infiltrate of epidermal, rather than dermal, T cells. Additional tissue culture studies showed that UVB, in doses that might be expected to penetrate the epidermis, inhibited proliferation and induced cytotoxicity or apoptosis in T cells to a much greater degree than it did in keratinocytes. Coupling our results with earlier data showing that the epidermal pathology of psoriasis can be reversed by an IL-2 toxin, we conclude that UVB exerts its therapeutic effects principally at the level of activated epidermal T cells.

Materials and Methods

**UVB Treatment and Measurement.** Patients with extensive psoriasis (>10% body surface area affected) were hospitalized for inpatient UVB treatment on a modified "Goeckerman" protocol. Upon entry into the study, the patients had not been treated with systemic antipsoriatic medications for a minimum of 4 wk and had not been treated with topical agents for a minimum of 2 wk. For each patient, a minimum erythema dose (MED) was established before whole body irradiation, which was begun with a UVB dose 10-20% lower than the MED. For each subsequent day, the UVB dose was increased by 10% unless marked erythema developed. Treatment was terminated upon attainment of clinical clearing of psoriatic lesions, typically after 4-5 wk of daily treatment. (4 of 13 patients sequentially entered into this study did not respond to UVB treatment, and posttreatment effects were not studied in these nonresponders.) UVB treatment was given in conjunction with skin lubrication using petrolatum containing 3% crude coal tar, but the tar-containing preparation was removed from the skin before each irradiation. Skin was irradiated in a unit (model 57000; Psoralite Corp., Columbia, SC) containing LS-FS72T12-UVB-HO fluorescent bulbs, which emit in a broad peak of 285-345 nm except for a spike of increased irradiance at 313 nm. UVB output was metered with a radiometer (model IL1700; International Light, Newburyport, MA) and calibrated UVB detector (model SED 240; International Light). Irradiation of cultured cells was performed using a panel of smaller (24 in.) fluorescent bulbs with identical spectral output and metering with the same UVB detector.

**Histopathological Assessment.** 6-µm Cryostat sections were made on biopsies of unaffected skin and of lesional psoriatic skin taken immediately before the start of UVB treatment and again upon completion. All methods have been described (5). Briefly, immunohistochemical staining of tissue was performed as described (5) using 3-aminoo-9-ethylcarbazole as the chromagen, since its red reaction product could easily be distinguished from melanin. Mouse mAbs to α3-integrin were a gift from Dr. Anthony Albino (Memorial Sloan-Kettering Cancer Center, New York). Mouse mAbs to ICAM-1, clone RR1/1, were as previously described (18). Epidermal thickness was measured with a calibrated microscope ocular (5). Hematoxylin and eosin-stained tissue sections were prepared by a commercial laboratory from formalin-fixed, paraffin-embedded tissue.

**Cell Culture Analysis.** Keratinocytes were cultured from neonatal human skin using serum-free keratinocyte growth medium (Clonetics Corp., San Diego, CA) (5). Peripheral blood mononuclear cells were cultured in PHA-containing RPMI 1640 medium (5). A transformed T lymphocyte cell line (HUT 102) was maintained in RPMI 1640 medium containing 10% FCS. For UVB irradiation, cells were briefly switched to PBS and were irradiated in open-topped tissue culture plates, followed by replacement with the usual growth medium. Keratinocyte proliferation was measured by direct cell counting, and lymphocyte proliferation was determined by the incorporation of [3H]thymidine (5). Assessment of cell viability was performed by incubating cells for 90 min at room temperature in buffers containing a mixture of 2 mM calcinAM (viable cells) and 4 mM ethidium homodimer (dead cells) (both dyes were obtained from Molecular Probes, Inc., Eugene, OR). Fluorescence of calcin or ethidium was visualized using a Photomicroscope III (Carl Zeiss, Inc., Thornwood, NY) equipped with excitation and barrier filters for green and red fluorescence. Induction of DNA fragmentation or apoptosis was detected by the TUNEL (TdT-mediated dUTP-biotin nick end labeling) reaction as described (21). The TUNEL procedure was modified to include a 30-min wash with 0.01 M Tris-buffer and a brief wash with 10X Tris-buffered saline (pH 7.6) after incubation of cells with biotin-dUTP (Boehringer Mannheim Biochemicals, Indianapolis, IN) and TdT enzyme (Promega, Madison, WI). Controls included reactions in which TdT was omitted. Positive staining reactions were confirmed with a second detection system (digoxigenin-conjugated dUTP followed by peroxidase-conjugated sheep antidigoxigenin antibodies).

Results

The effects of phototherapy on epidermal and immunological activation in lesional psoriatic plaques were studied in nine patients, who responded to this form of therapy by clinical clearing of psoriatic lesions. For consistent delivery of phototherapy, all patients were treated as inpatients in our General Clinical Research Center and were closely observed for daily application of topical tar ointment and for development of phototoxicity on therapy. Increasing (sub-erythogenic) doses of UVB were delivered each day for an average treatment of 27 d (the cumulative exposure to UVB averaged 4.7 J/cm² per patient, which is equivalent to the MED) without development of phototoxicity on therapy. Increasing (sub-erythogenic) doses of UVB were delivered each day for an average treatment of 27 d (the cumulative exposure to UVB averaged 4.7 J/cm² per patient, which is equivalent
Effects of Phototherapy on Epidermal Pathology.

Psoriatic pathology is largely defined by a series of changes in the proliferation and differentiation characteristics of epidermal keratinocytes. In comparison with normal skin (or unaffected skin in psoriatics), lesional psoriasis is characterized by marked keratinocyte hyperplasia, by profound thickening of the epidermis (acanthosis), by incomplete terminal differentiation of keratinocytes (absent granular layer and nuclear retention in cornified epidermis [parakeratosis]), and by parakeratosis, an “alternate” or “regenerative” differentiation program that alters expression of epidermal proteins and cytokines (1, 2). A number of inflammatory alterations, considered below, also occur in active psoriatic lesions.

Upon the conclusion of phototherapy, as illustrated in Fig. 1, A and B, lesional psoriatic epidermis had markedly reduced acanthosis, a granular layer was typically restored and parakeratosis in the stratum corneum was resolved, although this layer was thicker than normal (Fig. 1 D). Nuclear retention (parakeratosis) was not observed in the stratum corneum of psoriatic lesions after phototherapy. Of note, however, were numerous mononuclear inflammatory cells that continued to be present in the dermis of UVB-treated psoriatic lesions (Fig. 1 B). Keratinocyte proliferation, as judged by expression of the Ki67 nuclear protein confined in cycling cells, was markedly reduced such that residual proliferating keratinocytes were confined to the basal layer (compare Fig. 1, C and D) as in normal skin. Filaggrin, a protein normally produced by keratinocytes undergoing terminal differentiation in the granular layer, was minimally expressed by lesional epidermis (Fig. 1 E) but highly expressed by psoriatic keratinocytes following UVB treatment (Fig. 1 F). Because a visible granular layer is produced by the action of filaggrin to aggregate keratin filaments, the restored granular layer after phototherapy probably results from increased production of filaggrin by differentiating keratinocytes.

Fig. 2 presents quantitative analyses of these changes. The thickness of the epidermis was quantified separately for viable layers (stratum Malpighi) and cornified layers. Phototherapy reduced epidermal thickness by 60%, with reductions evident in both the stratum Malpighi and the stratum corneum (P <0.001). We noted that epidermal thickness of nonlesional skin was somewhat greater after phototherapy (101 versus 137 µm, P = 0.07) and that a statistically significant increase in thickness of the stratum corneum (25 versus 37 µm, P = 0.03) also could be measured (Fig. 2 A). The stratum corneum of treated plaques (Fig. 1 D), as well as the unaffected epidermis (not shown), appeared visibly thicker than unaffected skin before phototherapy. Keratinocyte proliferation was also consistently reduced by phototherapy, with an average reduction of 69% (P <0.001) (Fig. 2 B).

Regenerative differentiation of the epidermis is the term used to describe a transient phenotype associated with a
wound-repair response (1, 2). Lesional psoriatic epidermis consistently displays this phenotype, which is marked by altered expression of keratin 16, α3-integrin, IGF-1 receptors, and the differentiation-associated proteins involucrin and filaggrin (2, 20, 21). In nine out of nine cases, we observed that UVB reversed the regenerative epidermal growth. Keratin 16, for example, was expressed by suprabasal keratinocytes in all psoriatic lesions before treatment (Fig. 1 G), and it was absent from lesional epidermis after phototherapy (Fig. 1 H). α3-Integrin was expressed in lesional epidermis (Fig. 1 I) by both basal and suprabasal keratinocytes, but after phototherapy (Fig. 1 J) its expression was predominantly basal, as in normal epidermis. Expression of involucrin and of IGF-1 receptors was also normalized to the suprabasal and basal layers, respectively (not shown). In sum, all the known changes in the regenerative epidermal growth pattern were coordinately reduced by phototherapy of active psoriatic plaques.

Effects of Phototherapy on Tissue Infiltration by T Lymphocyte Subsets. The appearance of CD8+, CD4+, and CD1+ cells in lesional psoriatic tissue before and after phototherapy is illustrated in Fig. 3. These micrographs illustrate numerous CD8+ lymphocytes in diseased epidermis and dermis before treatment (Fig. 3 A) but only a marked reduction of CD8+ lymphocytes in the epidermis after phototherapy (Fig. 3 B). CD4+ cells were common in the reticular dermis and in the papillary dermis, near the dermal–epidermal interface in lesional skin (Fig. 3 C). Some reduction in CD4+ cells was evident in the epidermal–dermal interface and in the upper papillary dermis after UVB treatment (Fig. 3 D). Fig. 4 presents a quantitative summary of T lymphocytes infiltrating the epidermis and dermis of lesional psoriatic tissue before and after phototherapy. As in earlier studies (4, 5), the T lymphocytes infiltrating the epidermis were predominantly CD8+, whereas those infiltrating the dermis were chiefly of the CD4+ phenotype (Fig. 4). Total (CD3+) T cells in the epidermis were reduced by an average of 91% (11-fold) by phototherapy (P <0.001), whereas these cells were reduced by a mean of only 19% (1.2-fold) in the dermis. The major T cell subset responding to phototherapy in the epidermis was CD8+, showing a mean reduction of 85% (P <0.001), whereas CD4+ cells were reduced by 49% (P <0.01). Expression of the IL-2 receptor α chain (CD25) was reduced to an even greater extent than was expression of T cells in the epidermis, with a mean reduction of 95% (21-fold, P <0.001) in the dermis, a 36% reduction in CD4+ cells and a 37% reduction in CD25+ cells were measured (Fig. 4). Interestingly, epidermal CD1+ (Langerhans) cells did not appear to be depleted, and even may have been increased, in epidermis of psoriatic lesions after phototherapy (Fig. 3, E and F). Although Langerhans cells were not strictly quantified after CD1 staining, neither

Figure 4. Quantitative analysis of T cell infiltration in psoriatic lesional tissue before and after UVB treatment. Top panels show mean numbers of CD3+, CD8+, CD4+, or CD25+ cells in the epidermis or dermis of psoriatic lesional tissue before treatment (solid bar) or after UVB treatment (hatched bar); standard error is shown for each mean value. P values for differences between untreated and UVB-treated tissue were P <0.001 (**), P <0.01 (**), P <0.05 (*), or P >0.05 (ns). Bottom panels display the relationship between reduction in epidermal acanthosis (thickness) and reduction in the number of total T lymphocytes (CD3+) in either the epidermis or dermis of biopsies analyzed for individual patients.
psoriatic lesional epidermis nor unaffected epidermis showed marked reductions in Langerhans cells at the conclusion of UVB treatment. In fact, the distribution of bone marrow-derived cells in psoriatic epidermis after phototherapy (few T lymphocytes, numerous Langerhans cells) is similar to that observed in normal skin or the unaffected skin of psoriasics. The presence of numerous residual T lymphocytes in psoriatic lesional skin after phototherapy, however, contrasts sharply with unaffected or normal skin, both of which contain only scant T lymphocytes outside the vasculature (5).

To illustrate further the relationship between epidermal activation and epidermal T cells, the lower panels of Fig. 4 graph the relationships between the reduction in epidermal or dermal CD3+ cells and the reduction in epidermal acanthosis produced by phototherapy. In individual cases, phototherapy reductions in epidermal thickness range from 43 to 80%, and reductions in epidermal CD3+ T cells range from 70 to 100%. The correlation coefficient of these reductions was 0.69 in relation to the magnitude in reduction of epidermal CD3+ cells (Fig. 4, lower left). In contrast, dermal CD3+ cells were reduced by a maximum of 58% or increased by up to 20% in individual cases, and these changes were poorly related to reductions in epidermal thickness (r = 0.18; Fig. 4, lower right).

The effect of phototherapy on expression of HLA-DR and ICAM-1 by keratinocytes in lesional psoriasis was also examined (Fig. 3, G–J). Although both of these proteins were produced by keratinocytes in active lesions (Fig. 3, G and J), little or no expression could be detected after phototherapy (Fig. 3, H and J). HLA-DR continued to be expressed by Langerhans cells in the epidermis after treatment (Fig. 3 H), and ICAM-1 was still produced by endothelium of papillary blood vessels and other dermal cells (Fig. 3 J).

Effects of UVB on Keratinocytes and Lymphocytes In Vitro. To distinguish among the possible cellular targets of phototherapy, we compared the ability of UVB to directly suppress the growth of keratinocytes and leukocytes. We used the same broad-band UVB fluorescent source (bulbs emit radiation over a broad band from 285 to 345 nm, with a sharp peak at 313 nm) with identical metering of output intensity. Cells were mock-irradiated or treated with 1–20 mJ/cm² UVB, and proliferation was measured after 1, 2, 3, or 4 d. Keratinocyte growth was minimally inhibited by 4 mJ/cm², moderately inhibited by 8–12 mJ/cm², and completely inhibited by 16–20 mJ/cm² (Fig. 5 A). In PHA-activated peripheral blood mononuclear leukocytes, 2 mJ/cm² of UVB produced detectable inhibition of lymphocyte growth 1–2 d after exposure, 4 mJ/cm² produced 65% inhibition 3 d after exposure, and complete inhibition was produced by ≥8 mJ/cm² (Fig. 5 B). A transformed T-lymphocyte cell line (HUT 102) was similarly sensitive to the antiproliferative effects of UVB (Fig. 5 C). Thus, lymphocytes appeared more sensitive than keratinocytes to the antiproliferative effects of UVB irradiation.

The inhibition of proliferation in lymphocytes and keratinocytes was associated with increased cellular cytotoxicity as assessed by fluorescent probes that distinguish viable from nonviable cells (Fig. 6). This assay scores for live cells by uptake of calceinAM (nonfluorescent substrate), which is converted by cellular esterases to calcine which emits green fluorescence. Conversely, esterase-negative cells with compromised plasma membranes (nonviable) do not cleave calcineAM but will allow ethidium homodimer to enter, and this is detected as red nuclear fluorescence. Hence, every
Figure 6. Comparative study of cytotoxic effects of UVB in human keratinocytes or leukocytes in vitro. Micrographs are shown for PBMC (A–C) or keratinocytes (D–F) after incubation of cells in calceinAM (substrate for green fluorescence, live cells) and ethidium dimer (red fluorescence, dead cells). Lymphocytes were mock irradiated and examined after 72 h in culture (A), or they were irradiated with 8 mJ/cm² and examined after 24 (B) or 72 h (C). Keratinocytes were examined 72 h after irradiation with 16 (D) or 64 mJ/cm² (E and F). Micrographs for E and F show the same field of cells photo-
cell visualized in an assay can be scored for viability or non-viability. Exposure of lymphocytes to 8 mJ/cm² of UVB led to massive cell death (>90% nonviable cells) 3 d after UVB exposure (Fig. 6, A–C). Lethality was not immediately evident, since lymphocytes were fully viable 1 d after exposure to 8 mJ/cm² UVB. Exposure of lymphocytes to 4 mJ/cm² produced ~50% cell death at 3 d using this assay, whereas exposure to 2 mJ/cm² produced <20% cell death. In contrast, keratinocytes were more resistant to the cytotoxic effects of UVB. 3 d after exposure to 8 or 16 mJ/cm², keratinocytes appeared fully viable (Fig. 6 D). Exposure to 64 mJ/cm² produced death in ~50% of keratinocytes (Fig. 6, E–F), a level of cytotoxicity produced in lymphocytes after exposure to only 4 mJ/cm² of UVB. Keratinocytes treated with 64 mJ/cm² showed cytoplasmic blebbing characteristic of apoptosis (22).

To explore further the ability of UVB to induce apoptosis in lymphocytes or keratinocytes, cells that had been UVB treated were examined for DNA fragmentation by the TUNEL procedure. Transformed lymphocytes or PBMC exposed to 8 mJ/cm² UVB showed clear TUNEL positivity 24–48 h after UVB treatment. Fig. 6 H illustrates TUNEL positivity in both intact nuclei (arrows) and in nuclear fragments (open arrows), which are morphological indicators of advanced apoptosis. As a control for the TUNEL reaction, Fig. 6 G shows absence of nuclear staining in UVB-treated lymphocytes when only TdT enzyme was omitted from the reaction. In contrast to the lymphocyte results, no significant TUNEL reactivity was detected in cultured keratinocytes 1–3 d after exposure to 1–16 mJ/cm² UVB (Fig. 6 I), but some TUNEL-positive cells could be detected after exposure to 64 mJ/cm² (not shown). Thus, TUNEL reactivity paralleled viability measurements made in keratinocytes with calcine/ethidium uptake. Both viability and TUNEL reactions indicate greater lethality of UVB in lymphocytes than in epidermal keratinocytes, and the TUNEL reactions suggest that apoptosis is induced in lymphocytes after exposure to relatively low levels of UVB.

**Discussion**

One of the most common treatments for moderately severe psoriasis is skin irradiation with UVB, often given after skin lubrication with tar-containing emollients. A number of earlier studies have demonstrated effects of UVB on normal skin that are paradoxical in relationship to therapeutic improvements. In normal skin, UVB increases TGF-α synthesis by keratinocytes, accelerates keratinocyte proliferation, and increases overall epidermal thickness (23–25). Several cytokines thought to initiate or enhance psoriatic pathology are also increased after UVB irradiation of skin or cultured keratinocytes: IFN-γ (25), TNF-α (20, 26), IL-1 (27), IL-6 (28) and IL-8 (29). Furthermore, UVB irradiation increases leukocytic infiltration (30) and activates neutrophil effector functions (31). Therefore, it might be anticipated that UVB treatment of psoriatic skin would worsen hyperplasia and inflammation in lesions, but the entirely opposite effect was observed. We observed reduced epidermal thickness, diminished keratinocyte proliferation, decreased abundance of immunoreactive IL-6 in lesional tissue (32), and virtual elimination of interferon-γ–induced proteins (HLA-DR and ICAM-1) in psoriatic keratinocytes. In effect, UVB treatment reversed the hyperplasia and regenerative growth to levels associated with normal skin, even though existing evidence predicted the opposite.

One explanation for this paradox is that UVB may operate primarily on T lymphocytes in psoriatic tissue. In fact, UVB treatment produced consistent and profound depletion of T lymphocytes from psoriatic epidermis. T cell activation appeared to be decreased even further, as judged by expression of the IL-2 receptor α chain (CD25). Dermal lymphocytes were much less affected by UVB treatment. Our observations clearly oppose the view that therapy-related improvements are mediated by increased numbers of epidermal lymphocytes (33).

As used therapeutically, 5–10% of incident radiation in the UVB spectrum should penetrate the epidermis to the basal layer (the remaining energy is scattered at the epidermal surface or is absorbed by keratinocyte proteins or other molecules) (34). Our psoriatics were treated on a daily basis with UVB averaging 174 mJ/cm². Thus, at the midpoint of therapy, one would expect an average penetration of 8–17 mJ/cm² to the basal layer. UVB penetration beyond the basal layer would be rapidly attenuated by the dermal–epidermal interface and upper dermis (34). Irradiation of transformed lymphocytes or mitogen-activated PBMC with 4–8 mJ/cm² of UVB in vitro immediately inhibited proliferation and then induced apoptotic cell death over a somewhat longer time frame. Thus, the expected delivery of UVB to psoriatic epidermis near the midpoint of therapy approximates the energy levels sufficient to kill activated lymphocytes. The minimal penetration of UVB into dermal tissue is then the most logical explanation for the minimal effects of UVB observed on dermal lymphocytes. In contrast, keratinocytes appear to be relatively resistant to the cytotoxic effects of UVB, since UVB was cytotoxic for keratinocytes at levels that were at least 10-fold higher than those for lymphocytes. The deletion of activated lymphocyte clones from psoriatic tissue might then explain the "remittive" nature of UVB treatment, i.e., its ability to produce sustained therapeutic improvement, whereas noncytotoxic immunosuppressive agents, e.g., corticosteroids or cyclosporine, do not produce this sustained therapeutic benefit (5).

UVB might also exert immunosuppressive actions inde-
pendent of direct cell cytotoxicity in the psoriatic lesions. In human skin, direct UVB irradiation ablates or reduces contact hypersensitivity to a number of antigens (14, 15, 35). In various systems, UVB depletes Langerhans cells from the epidermis, decreases the activation capability of residual Langerhans cells, and decreases the ability of Langerhans cells to present viral antigens to lymphocytes (15, 35–39). UVB also alters tyrosine phosphorylation of T lymphocyte proteins, inhibiting T cell activation but not directly inducing cytotoxicity (40). UVB also increases synthesis of αs-urocanic acid, IL-10, the IL-1 receptor antagonist, and TGF-β, which are all potentially immunosuppressive mediators (14, 41, 42). Thus CD25 expression in UVB-treated psoriatic epidermis, which is reduced overall more than are T cells, might be modulated via decreased antigen–APC interactions or by chemical mediators. The number of Langerhans cells in UVB-treated skin, however, did not appear to be reduced by repetitive UVB exposures (Fig. 4 F), an observation that suggests that UVB selectively affects the T lymphocytes that infiltrate psoriatic epidermis. The apparently minimal effects of UVB on Langerhans cells might reflect their relative resistance to suberythrogenic UVB levels. It is possible, however, that continued trafficking of Langerhans cells into the epidermis might replace those cells damaged by repetitive UVB exposure.

Intensive UVB treatment of psoriasis leads to relatively durable clinical remission (5, 43). Our data establish that a major cellular correlate of this outcome is the elimination of intraepidermal lymphocytes and restoration of a normal growth/differentiation sequence in the epidermis. Psoralen + UVA (PUVA) treatment has similar effects on the elimination of epidermal T lymphocytes, the reversal of regenerative epidermal growth, and clinical remissions (5). These data, when considered with effects produced by DAB319IL-2 and other more selective antilymphocyte agents (11), suggest that disease-mediating lymphocytes reside primarily in the epidermis or at the dermal–epidermal interface, where T cells could exert direct effects on epidermal keratinocytes. The predominant epidermal lymphocytes are CD8+, and a recent report indicates that these CD8 cells contain only a limited number of clones (9). The association of MHC class I alleles with disease susceptibility, the selective accumulation of CD8+ lymphocytes in the epidermis, and clonality in CD8+, but not CD4+ cells (9), imply that specific immune activation is MHC class I restricted in psoriasis. Epidermal cells could be important targets of effector CD8+ cells. Keratinocyte injury produced by CTLs in the epidermis might trigger these cells into a repair or regenerative program, or, alternatively, cytokines elaborated by activated CD8+ lymphocytes might directly stimulate keratinocyte proliferation (44). Some cytokines that are elevated in psoriatic lesions, e.g., IL-2, IL-6, and IFN-γ, may promote efficient maturation of immature CD8+ lymphocytes into effector CTLs (45, 46), and IFN-γ can enhance CD8+-mediated injury to keratinocytes by modulating MHC class I expression (47).

Although either CD4+ or CD8+ lymphocytes could elaborate disease-associated cytokines, the majority of CD4+ clones isolated from psoriatic lesions elaborate cytokines that suppress keratinocyte proliferation (44). The pathogenic significance of CD4+ lymphocytes in psoriatic tissue is thus somewhat uncertain. CD4+ lymphocytes are frequently abundant in MHC class I–restricted inflammatory tissue reactions mediated by effector CD8+ lymphocytes (48). For example, in cutaneous GVH reactions, many CD8+ effector lymphocytes are localized in the epidermis (49), but the majority of dermal lymphocytes are CD4+ (50), as in psoriatic tissue. Since the CD4+ lymphocytes that have been analyzed from psoriatic lesions display no preferential TCR usage (9), infiltration by this cell type, though quantitatively dominant in the dermis, may reflect nonspecific recruitment by inflammatory cytokines and altered vascular adhesion molecules (51). Furthermore, since most dermal T lymphocytes persist in psoriatic dermis after UVB treatment, it appears that these cells are not immediately pathogenic. In fact, the most direct explanation for the prolonged clinical remissions that are obtained with UVB or PUVA therapies is that probably through cytotoxic actions, these modalities produce profound depletion of effector lymphocytes residing at the dermal–epidermal interface or in the epidermis (5). Longer periods of clinical remission attained by PUVA treatment might be best explained by the treatment's ability to deplete more dermal lymphocytes from psoriatic skin than UVB treatment does (5). In turn, these findings suggest a rational basis for use of specific immune-modulating agents to treat psoriasis and to potentially decrease inadvertent toxicity–associated effects on epidermal keratinocytes.

This work was supported by a General Clinical Research grant (M01-RR-00102) from the National Institutes of Health (NIH) to The Rockefeller University Hospital, by NIH grants CA-54215 and AR-07525, and by grants from Beatrice Renfield, Sue Weil, the Herzog Foundation, the American Skin Association, and the Carson Family Charitable Trust.

Address correspondence to James G. Krueger, M.D., Box 1, The Rockefeller University, 1230 York Ave., New York, NY 10021.

Received for publication 20 May 1995 and in revised form 10 July 1995.
References

1. Mansbridge, J.N., and A.M. Knapp. 1987. Changes in keratinocyte maturation during wound healing. J. Invest. Dermatol. 89:253–263.

2. Hertle, M.D., M.-D. Kubler, I.M. Leigh, and F.M. Watt. 1992. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J. Clin. Invest. 89:1892–1901.

3. Krane, J.F., D.P. Murphy, A.B. Gottlieb, H. Uyttendaele, D.M. Carter, and J.G. Krueger. 1993. Insulin-like growth factor-1 (IGF-1) receptor expression may regulate keratinocyte proliferative potential in normal and psoriatic epidermis. J. Invest. Dermatol. 96:544.

4. Bos, J.D., C. Hagenoars, S.R. Krieg, W.J. Voorn, and M.L. Kapsenberg. 1989. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased skin. Arch. Dermatol. Res. 281:24–30.

5. Vallat, V.P., P. Gilleaudeau, L. Battat, J. Wolfe, R. Nabeya, N. Heftler, E. Hodak, A.B. Gottlieb, and J.G. Krueger. 1994. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J. Exp. Med. 180:283–296.

6. Gottlieb, A.B., and J.G. Krueger. 1993. The role of activated T lymphocytes in the pathogenesis of psoriasis. In Psoriasis. L. Dubertret, editor. ISED, Brescia, Italy. 63–71.

7. Baadsgaard, O., G. Fisher, J.J. Voorhees, and K.D. Cooper. 1990. The role of the immune system in the pathogenesis of psoriasis. J. Invest. Dermatol. 95:325–345.

8. Henseler, T., and E. Christophers. 1985. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Amer. Acad. Dermatol. 13:450–456.

9. Chang, J.C.C., L.R. Smith, K.J. Froning, B.J. Schwabe, J.A. Laxer, L.L. Caralli, H.H. Kurland, M.A. Karasek, D.I. Wilkinson, D.J. Carlo, and S.W. Brostoff. 1994. CD8+ T cells in psoriatic lesions preferentially use T-cell receptor VR3 and/or Vβ13.1 genes. Proc. Natl. Acad. Sci. USA. 91:9282–9286.

10. Bos, J.D., C. Hagenoars, S.R. Krieg, W.J. Voorn, and M.L. Kapsenberg. 1989. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch. Dermatol. Res. 281:24–30.

11. Gottlieb, S.L., P. Gilleaudeau, R. Johnson, L. Estes, T.G. Woodworth, A.B. Gottlieb, and J.G. Krueger. 1995. Response of psoriasis to a lymphocyte-selective toxin (DABim-L2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Medicine. 1:442–447.

12. Gottlieb, A.B., R.M. Grossman, L. Khandke, D.M. Carter, P.B. Sehgal, S.M. Fu, A. Granelli-Piperno, M. Rivas, L. Barazani, and J.G. Krueger. 1992. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J. Invest. Dermatol. 98:302–309.

13. Krueger, J.G., L. Staiano-Coico, B. Smoller, M. Anzilotti, V.P. Vallat, P. Gilleaudeau, and A.B. Gottlieb. 1995. Endogenous growth factor pathways may regulate epidermal hyperplasia in chronic venous wounds: modulation by hydrocolloid dressings. In Wound Healing and Skin Physiology. Altreyer, et al., editors. Springer-Verlag, Berlin. pp. 285–302.

14. Tokura, Y. 1992. Mechanisms of local, low-dose UVB-induced immunosuppression in contact hypersensitivity. J. Dermatol. 19:923–931.

15. Friedmann, P.S. 1990. The immunology of allergic contact dermatitis: the DNCB story. Adv. Dermatol. 5:175–195.

16. Bazar, L.S., and H.J. Deeg. 1992. Ultraviolet B-induced DNA fragmentation (apoptosis) in activated T-lymphocytes and Jurkat cells is augmented by inhibition of RNA and protein synthesis. Exp. Hematol. 20:80–86.

17. Teunissen, M.B., R.M. Sylva-Steenland, and J.D. Bos. 1993. Effect of low-dose ultraviolet-B radiation on the function of human T lymphocytes in vitro. Clin. Exp. Immunol. 94:208–213.

18. Dustin, M.L., R.K. Singer, D.T. Tuck, and T.A. Springer. 1988. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J. Exp. Med. 167:1323–1340.

19. Gavrieli, Y., Y. Sherman, and S.A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493–501.

20. Trefzer, U., M. Brockhaus, H. Loetscher, F. Parlow, A. Budnik, M. Grewe, H. Christoph, A. Kapp, E. Schoepf, T.A. Luger, and J. Krutmann. 1993. The 55-kD tumor necrosis factor receptor on human keratinocytes is regulated by tumor necrosis factor-alpha and by ultraviolet B radiation. J. Clin. Invest. 92:462–470.

21. Krane, J.F., A.B. Gottlieb, D.M. Carter, and J.G. Krueger. 1992. The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor. J. Exp. Med. 175:1081–1090.

22. Casciola-Rosen, L.A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179:1317–1330.

23. James, L.C., A.M. Moore, L.A. Wheeler, G.A. Murphy, P.M. Dowd, and M.W. Greaves. 1991. Transforming growth factor alpha: in vivo release by normal human skin following UV irradiation and abrasion. Skin. Pharmacol. 4:61–64.

24. Murphy, G.M., D.G. Quinn, R.D.R. Camp, J.L.M. Hawk, and M.W. Greaves. 1991. In-vivo studies of the action spectrum and time course for release of transforming growth factor-α by ultraviolet irradiation in man. Br. J. Dermatol. 125:566–568.

25. Livden, J.K., J.R. Bjerke, M. Degreve, and M. Matre. 1986. The effect of Goeckerman therapy on interferon in serum and suction blister fluid from patients with psoriasis. Br. J. Dermatol. 114:217–225.

26. Kock, A., T. Schwarz, R. Kirnbauer, A. Urbanski, P. Perry, J.C. Ansel, and T.A. Luger. 1990. Human keratinocytes are a source of tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J. Exp. Med. 172:1609–1614.

27. Konnikov, N., S.H. Pincus, and C.A. Dinarello. 1989. Elevated plasma interleukin-1 levels in humans following ultraviolet light therapy for psoriasis. J. Invest. Dermatol. 92:235–239.

28. Kirnbauer, R., A. Kock, P. Neuner, E. Forster, J. Krutmann, A. Urbanski, E. Schauer, J.C. Ansel, T. Schwarz, and T.A. Luger. 1991. Regulation of epidermal cell interleukin-6 production by UV light and corticosteroids. J. Invest. Dermatol. 96:484–489.

29. Kondo, S., T. Kono, D.N. Sauder, and R.C. McKenzie.
1993. IL-8 gene expression and production in human keratinocytes and their modulation by UVB. J. Invest. Dermatol. 101:690-694.

30. Soter, N.A. 1990. Acute effects of ultraviolet radiation on the skin. Sem. Dermatol. 9:11-15.

31. Savage, J.E., A.J. Theron, and R. Anderson. 1993. Activation of neutrophil membrane-associated oxidative metabolism by ultraviolet radiation. J. Invest. Dermatol. 101:532-536.

32. Grossman, R.M., J. Krueger, D. Yourish, A. Granelli-Piperno, D.P. Murphy, L.T. May, T.S. Kupper, P.B. Schgal, and A.B. Gottlieb. 1989. Interleukin-6 (IL-6) is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. USA. 86:6367-6371.

33. Baker, B., H. Valdimarsson, J.N. Leonard, C.E.M. Griffiths, and L. Fry. 1984. The action of topical steroids, dithranol, and PUVA on T lymphocytes and dendritic cells in psoriasis. Br. J. Dermatol. 111:702.

34. Anderson, R.R., and J.A. Parrish. 1981. The optics of human skin. J. Invest. Dermatol. 77:13-19.

35. Mommaas, A.M., A.A. Mulder, M. Vermeer, B.W. Boom, C. Tseng, J.R. Taylor, and J.W. Streilein. 1993. Ultrastructural studies bearing on the mechanism of UVB-impaired induction of contact hypersensitivity to DNCB in man. Exp. Immunol. 92:487-493.

36. Murphy, G.M., P.G. Norris, A.R. Young, M.F. Corbett, and J.L.M. Hawk. 1993. Low-dose ultraviolet-B irradiation depletes human epidermal Langerhans cells. Br. J. Dermatol. 129:674-677.

37. Van Praag, M.C.G., A.A. Mulder, F.H.J. Claas, B.-J. Vermeer, and A.M. Mommaas. 1994. Long-term ultraviolet-B-induced impairment of Langerhans cell function: an immunoelectron microscopic study. Clin. Exp. Immunol. 95:73-77.

38. Krutmann, J., I.U. Khan, R.S. Walls, F. Zhang, E.A. Rich, J.J. Ellner, and C.A. Elnets. 1990. Cell membrane is a major locus for ultraviolet-B-induced alterations in accessory cells. J. Clin. Invest. 85:1529-1636.

39. Krutmann, J.K., G.M. Kammer, Z. Toossi, R.L. Waller, J.J. Ellner, and C.A. Elnets. 1990. UVB radiation and human monocyte accessory function: differential effects on premitotic events in T-cell activation. J. Invest. Dermatol. 92:204-209.

40. Schieven, G.L., J.M. Kirihara, L.K. Gilliland, F.M. Uckun, and J.A. Ledbetter. 1993. Ultraviolet radiation rapidly induces tyrosine phosphorylation and calcium signaling in lymphocytes. Mol. Biol. Cell. 4:523-530.

41. Gilmour, J.W., J.P. Vestey, and M. Norval. 1993. The effect of UV therapy on immune function in patients with psoriasis. Br. J. Dermatol. 129:28-38.

42. Kang, K., C. Hammarberg, L. Meunier, and K.D. Cooper. 1994. CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potently produce IL-10 and represent the major secretory source of epidermal IL-10 protein. J. Immunol. 153:5256-5264.

43. Larko, O. 1982. Phototherapy of psoriasis—clinical aspects and risk evaluation. Acta Dermato-Venerologica. 103(Suppl.) 1-42.

44. Prinz, J.C., B. Gross, S. Vollmer, P. Trommler, I. Strobel, M. Meurer, and G. Plewig. 1994. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products. Eur. J. Immunol. 24:593-598.

45. Wuehlbrandt, P.F., H. Quintenmeier, and E. Schmitt. 1991. Involvement of interleukin-1 (IL-1), IL-6, IL-2, and IL-4 in generation of cytolytic T cells from thymocytes stimulated by a Mycoplasma fermentans-derived product. Infect. Immunol. 59:3962-3968.

46. Fink, S., S. de la Barrera, F. Minnucci, R. Valdez, L.M. Balina, and M.C. Sasiain. 1993. IFN-γ, IL-6 and IL-4 modulate M. leprae- or PPD-specific cytotoxic T cells in leprosy patients. Scand. J. Immunol. 38:551-558.

47. Ritter, M., C. Huber, J. Auboeck, H. Pohl-Markl, J. Tropfmaier, M. Herold, A. Gaechter, W. Nussbaumer, G. Boeck, D. Nachbaurn, et al. 1994. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status. Immunology. 81:569-577.

48. Doherty, P.C., J.E. Allan, F. Lynch, and R. Ceredig. 1990. Dissection of an inflammatory process induced by CD8+ T cells. Immunol. Today. 11:55-59.

49. Sale, G.E., P. Anderson, M. Brown, and D. Myerson. 1992. Evidence of cytotoxic T-cell destruction of epidermal cells in human graft-vs-host disease. Immunohistology with monoclonal antibody T1A-1. Arch. Pathol. Lab. Med. 116:622-625.

50. Paller, A.S., A. Nelson, L. Steffen, L. Gottschalk, and H. Kaizer. 1988. T-lymphocyte subsets in the lesional skin of allogeneic and autologous bone marrow transplant patients. Arch. Dermatol. 124:1795-1801.

51. Nickoloff, B.J. 1991. The cytokine network in psoriasis. Arch. Dermatol. 127:871-884.